The Social Market Foundation (SMF), an influential think tank, has published a report on a proposed new approach to the way that the NHS purchases drugs. It states that if the NHS adopted an outcomes-based approach to the reimbursement of medicines, it could result in better value for money and faster patient access. At present, the effectiveness of drugs is assessed prior to the treatment being available to patients, the report proposes that this process is reversed. Report author and SMF research director Nigel Keohane said that “given the NHS spends £17bn on medicines each year, the reforms would also steer manufacturers to develop innovative drugs that can make the largest improvements to patient health.” Barak Palatchi, Oncology General Manager, Novartis UK & Ireland agreed, stating that “we need a different approach so the health system is sustainable, delivering better economic value over the long-term, and ensuring better patient outcomes”
The report can be read here.